Adient Medical Develop Absorbable IVC Filter To Prevent Pulmonary Embolism

Adient Medical Develop Absorbable IVC Filter To Prevent Pulmonary Embolism
Pulmonary embolism is a common and potentially fatal condition where a blood clot cause a blockage in one of the pulmonary arteries in the lungs. Patient at risk can be identified and are usually treated with anticoagulation therapy. However, when this is contraindicated or there are additional risk factors, inferior vena cava (IVC) filters, a physical net that catches clots before making it to the lungs, are commonly used to reduce risk of pulmonary embolism. While effective, they have serious drawbacks. In fact, over time pieces can fragment off, occlude blood flow, potentially becoming a source of thrombi themselves. Because of this, they are often retrieved after a period of time, carrying both high risks and costs.

The Texas-based startup Adient Medical is developing the first absorbable IVC filter for the prevention of pulmonary embolism. Just like any other IVC filter, it is able to trap blood clots destined for the lungs. Uniquely, it maintains 80 percent of its strength for 35 days before breaking down into CO2 and H2O after clots resorb in the filter. By doing so, the filter avoid the need for risky and costly retrieval procedures and cannot perforate organs, which has previously led to FDA warnings with conventional filters.

While most patients at risk of pulmonary embolism can be effectively treated with anticoagulation drugs, they are also inefficient or not safe to use in many patients. These patients rely on IVC filters, which despite their risks are considered advantageous. Not only are there risks associated with removing these filters, complications may even prevent them from being removed. And the long-term safety profile of permanently leaving a filter inside the body is unknown. Adient Medical’s innovative absorbable filter will disrupt the market, obviating the retrieval of the filter and potentially saving up to $12,000 per procedure. Most importantly, the startup has developed a technology that is safer than the current standard, reducing IVC-associated complications and risk, while potentially increasing quality and saving life.

Founded in 2012, Adient Medical has so far completed two animal studies that revealed a 100 percent clot capture efficacy and no pulmonary embolism, and they are expecting to bring the filters to human clinical trials in 2017. The startup has previously won the 2014 Rice Alliance Award, 2015 Medical World Americas, as well as a top 100 Red Herring award, that highlight the most exciting startups around the world. Adient was also a 2016 second place winner of the Medtech Innovator Competition, and won their Value Award for the company with the most attractive value proposition.